Table of Contents 1 Report Overview 1.1 Study Scope 1.2 Key Market Segments 1.3 Players Covered: Ranking by Oligonucleotide Therapeutics Revenue 1.4 Market Analysis by Type 1.4.1 Global Oligonucleotide Therapeutics Market Size Growth Rate by Type: 2020 VS 2026 1.4.2 Antisense Oligonucleotide 1.4.3 Aptamer 1.4.4 Other 1.5 Market by Application 1.5.1 Global Oligonucleotide Therapeutics Market Share by Application: 2020 VS 2026 1.5.2 Neuromuscular Diseases 1.5.3 ATTR 1.5.4 Hepatic VOD 1.5.5 Other 1.6 Study Objectives 1.7 Years Considered 2 Global Growth Trends by Regions 2.1 Oligonucleotide Therapeutics Market Perspective (2015-2026) 2.2 Oligonucleotide Therapeutics Growth Trends by Regions 2.2.1 Oligonucleotide Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 Oligonucleotide Therapeutics Historic Market Share by Regions (2015-2020) 2.2.3 Oligonucleotide Therapeutics Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Porter’s Five Forces Analysis 2.3.5 Oligonucleotide Therapeutics Market Growth Strategy 2.3.6 Primary Interviews with Key Oligonucleotide Therapeutics Players (Opinion Leaders) 3 Competition Landscape by Key Players 3.1 Global Top Oligonucleotide Therapeutics Players by Market Size 3.1.1 Global Top Oligonucleotide Therapeutics Players by Revenue (2015-2020) 3.1.2 Global Oligonucleotide Therapeutics Revenue Market Share by Players (2015-2020) 3.1.3 Global Oligonucleotide Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.2 Global Oligonucleotide Therapeutics Market Concentration Ratio 3.2.1 Global Oligonucleotide Therapeutics Market Concentration Ratio (CR5 and HHI) 3.2.2 Global Top 10 and Top 5 Companies by Oligonucleotide Therapeutics Revenue in 2019 3.3 Oligonucleotide Therapeutics Key Players Head office and Area Served 3.4 Key Players Oligonucleotide Therapeutics Product Solution and Service 3.5 Date of Enter into Oligonucleotide Therapeutics Market 3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026) 4.1 Global Oligonucleotide Therapeutics Historic Market Size by Type (2015-2020) 4.2 Global Oligonucleotide Therapeutics Forecasted Market Size by Type (2021-2026) 5 Oligonucleotide Therapeutics Breakdown Data by Application (2015-2026) 5.1 Global Oligonucleotide Therapeutics Market Size by Application (2015-2020) 5.2 Global Oligonucleotide Therapeutics Forecasted Market Size by Application (2021-2026) 6 North America 6.1 North America Oligonucleotide Therapeutics Market Size (2015-2020) 6.2 Oligonucleotide Therapeutics Key Players in North America (2019-2020) 6.3 North America Oligonucleotide Therapeutics Market Size by Type (2015-2020) 6.4 North America Oligonucleotide Therapeutics Market Size by Application (2015-2020) 7 Europe 7.1 Europe Oligonucleotide Therapeutics Market Size (2015-2020) 7.2 Oligonucleotide Therapeutics Key Players in Europe (2019-2020) 7.3 Europe Oligonucleotide Therapeutics Market Size by Type (2015-2020) 7.4 Europe Oligonucleotide Therapeutics Market Size by Application (2015-2020) 8 South America 8.1 South America Oligonucleotide Therapeutics Market Size (2015-2020) 8.2 Oligonucleotide Therapeutics Key Players in South America (2019-2020) 8.3 South America Oligonucleotide Therapeutics Market Size by Type (2015-2020) 8.4 South America Oligonucleotide Therapeutics Market Size by Application (2015-2020) 9 China 9.1 China Oligonucleotide Therapeutics Market Size (2015-2020) 9.2 Oligonucleotide Therapeutics Key Players in China (2019-2020) 9.3 China Oligonucleotide Therapeutics Market Size by Type (2015-2020) 9.4 China Oligonucleotide Therapeutics Market Size by Application (2015-2020) 10 Japan 10.1 Japan Oligonucleotide Therapeutics Market Size (2015-2020) 10.2 Oligonucleotide Therapeutics Key Players in Japan (2019-2020) 10.3 Japan Oligonucleotide Therapeutics Market Size by Type (2015-2020) 10.4 Japan Oligonucleotide Therapeutics Market Size by Application (2015-2020) 11Key Players Profiles 11.1 Biogen 11.1.1 Biogen Company Details 11.1.2 Biogen Business Overview and Its Total Revenue 11.1.3 Biogen Oligonucleotide Therapeutics Introduction 11.1.4 Biogen Revenue in Oligonucleotide Therapeutics Business (2015-2020)) 11.1.5 Biogen Recent Development 11.2 Sarepta Therapeutics 11.2.1 Sarepta Therapeutics Company Details 11.2.2 Sarepta Therapeutics Business Overview and Its Total Revenue 11.2.3 Sarepta Therapeutics Oligonucleotide Therapeutics Introduction 11.2.4 Sarepta Therapeutics Revenue in Oligonucleotide Therapeutics Business (2015-2020) 11.2.5 Sarepta Therapeutics Recent Development 11.3 Jazz Pharmaceuticals 11.3.1 Jazz Pharmaceuticals Company Details 11.3.2 Jazz Pharmaceuticals Business Overview and Its Total Revenue 11.3.3 Jazz Pharmaceuticals Oligonucleotide Therapeutics Introduction 11.3.4 Jazz Pharmaceuticals Revenue in Oligonucleotide Therapeutics Business (2015-2020) 11.3.5 Jazz Pharmaceuticals Recent Development 11.4 Bausch & Lomb 11.4.1 Bausch & Lomb Company Details 11.4.2 Bausch & Lomb Business Overview and Its Total Revenue 11.4.3 Bausch & Lomb Oligonucleotide Therapeutics Introduction 11.4.4 Bausch & Lomb Revenue in Oligonucleotide Therapeutics Business (2015-2020) 11.4.5 Bausch & Lomb Recent Development 11.5 Alnylam Pharmaceuticals 11.5.1 Alnylam Pharmaceuticals Company Details 11.5.2 Alnylam Pharmaceuticals Business Overview and Its Total Revenue 11.5.3 Alnylam Pharmaceuticals Oligonucleotide Therapeutics Introduction 11.5.4 Alnylam Pharmaceuticals Revenue in Oligonucleotide Therapeutics Business (2015-2020) 11.5.5 Alnylam Pharmaceuticals Recent Development 11.6 Dynavax Technologies 11.6.1 Dynavax Technologies Company Details 11.6.2 Dynavax Technologies Business Overview and Its Total Revenue 11.6.3 Dynavax Technologies Oligonucleotide Therapeutics Introduction 11.6.4 Dynavax Technologies Revenue in Oligonucleotide Therapeutics Business (2015-2020) 11.6.5 Dynavax Technologies Recent Development 11.7 Kastle therapeutics 11.7.1 Kastle therapeutics Company Details 11.7.2 Kastle therapeutics Business Overview and Its Total Revenue 11.7.3 Kastle therapeutics Oligonucleotide Therapeutics Introduction 11.7.4 Kastle therapeutics Revenue in Oligonucleotide Therapeutics Business (2015-2020) 11.7.5 Kastle therapeutics Recent Development 11.8 Akcea Therapeutics 11.8.1 Akcea Therapeutics Company Details 11.8.2 Akcea Therapeutics Business Overview and Its Total Revenue 11.8.3 Akcea Therapeutics Oligonucleotide Therapeutics Introduction 11.8.4 Akcea Therapeutics Revenue in Oligonucleotide Therapeutics Business (2015-2020) 11.8.5 Akcea Therapeutics Recent Development 12Analyst's Viewpoints/Conclusions 13Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Oligonucleotide Therapeutics Key Market Segments Table 2. Key Players Covered: Ranking by Oligonucleotide Therapeutics Revenue Table 3. Ranking of Global Top Oligonucleotide Therapeutics Manufacturers by Revenue (US$ Million) in 2019 Table 4. Global Oligonucleotide Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026 Table 5. Key Players of Antisense Oligonucleotide Table 6. Key Players of Aptamer Table 7. Key Players of Other Table 8. Global Oligonucleotide Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026 Table 9. Global Oligonucleotide Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026 Table 10. Global Oligonucleotide Therapeutics Market Size by Regions (2015-2020) (US$ Million) Table 11. Global Oligonucleotide Therapeutics Market Share by Regions (2015-2020) Table 12. Global Oligonucleotide Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million) Table 13. Global Oligonucleotide Therapeutics Market Share by Regions (2021-2026) Table 14. Market Top Trends Table 15. Key Drivers: Impact Analysis Table 16. Key Challenges Table 17. Oligonucleotide Therapeutics Market Growth Strategy Table 18. Main Points Interviewed from Key Oligonucleotide Therapeutics Players Table 19. Global Oligonucleotide Therapeutics Revenue by Players (2015-2020) (Million US$) Table 20. Global Oligonucleotide Therapeutics Market Share by Players (2015-2020) Table 21. Global Top Oligonucleotide Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Oligonucleotide Therapeutics as of 2019) Table 22. Global Oligonucleotide Therapeutics by Players Market Concentration Ratio (CR5 and HHI) Table 23. Key Players Headquarters and Area Served Table 24. Key Players Oligonucleotide Therapeutics Product Solution and Service Table 25. Date of Enter into Oligonucleotide Therapeutics Market Table 26. Mergers & Acquisitions, Expansion Plans Table 27. Global Oligonucleotide Therapeutics Market Size by Type (2015-2020) (Million US$) Table 28. Global Oligonucleotide Therapeutics Market Size Share by Type (2015-2020) Table 29. Global Oligonucleotide Therapeutics Revenue Market Share by Type (2021-2026) Table 30. Global Oligonucleotide Therapeutics Market Size Share by Application (2015-2020) Table 31. Global Oligonucleotide Therapeutics Market Size by Application (2015-2020) (Million US$) Table 32. Global Oligonucleotide Therapeutics Market Size Share by Application (2021-2026) Table 33. North America Key Players Oligonucleotide Therapeutics Revenue (2019-2020) (Million US$) Table 34. North America Key Players Oligonucleotide Therapeutics Market Share (2019-2020) Table 35. North America Oligonucleotide Therapeutics Market Size by Type (2015-2020) (Million US$) Table 36. North America Oligonucleotide Therapeutics Market Share by Type (2015-2020) Table 37. North America Oligonucleotide Therapeutics Market Size by Application (2015-2020) (Million US$) Table 38. North America Oligonucleotide Therapeutics Market Share by Application (2015-2020) Table 39. Europe Key Players Oligonucleotide Therapeutics Revenue (2019-2020) (Million US$) Table 40. Europe Key Players Oligonucleotide Therapeutics Market Share (2019-2020) Table 41. Europe Oligonucleotide Therapeutics Market Size by Type (2015-2020) (Million US$) Table 42. Europe Oligonucleotide Therapeutics Market Share by Type (2015-2020) Table 43. Europe Oligonucleotide Therapeutics Market Size by Application (2015-2020) (Million US$) Table 44. Europe Oligonucleotide Therapeutics Market Share by Application (2015-2020) Table 45. South America Key Players Oligonucleotide Therapeutics Revenue (2019-2020) (Million US$) Table 46. South America Key Players Oligonucleotide Therapeutics Market Share (2019-2020) Table 47. South America Oligonucleotide Therapeutics Market Size by Type (2015-2020) (Million US$) Table 48. South America Oligonucleotide Therapeutics Market Share by Type (2015-2020) Table 49. South America Oligonucleotide Therapeutics Market Size by Application (2015-2020) (Million US$) Table 50. South America Oligonucleotide Therapeutics Market Share by Application (2015-2020) Table 51. China Key Players Oligonucleotide Therapeutics Revenue (2019-2020) (Million US$) Table 52. China Key Players Oligonucleotide Therapeutics Market Share (2019-2020) Table 53. China Oligonucleotide Therapeutics Market Size by Type (2015-2020) (Million US$) Table 54. China Oligonucleotide Therapeutics Market Share by Type (2015-2020) Table 55. China Oligonucleotide Therapeutics Market Size by Application (2015-2020) (Million US$) Table 56. China Oligonucleotide Therapeutics Market Share by Application (2015-2020) Table 57. Japan Key Players Oligonucleotide Therapeutics Revenue (2019-2020) (Million US$) Table 58. Japan Key Players Oligonucleotide Therapeutics Market Share (2019-2020) Table 59. Japan Oligonucleotide Therapeutics Market Size by Type (2015-2020) (Million US$) Table 60. Japan Oligonucleotide Therapeutics Market Share by Type (2015-2020) Table 61. Japan Oligonucleotide Therapeutics Market Size by Application (2015-2020) (Million US$) Table 62. Japan Oligonucleotide Therapeutics Market Share by Application (2015-2020) Table 63. Biogen Company Details Table 64. Biogen Business Overview Table 65. Biogen Product Table 66. Biogen Revenue in Oligonucleotide Therapeutics Business (2015-2020) (Million US$) Table 67. Biogen Recent Development Table 68. Sarepta Therapeutics Company Details Table 69. Sarepta Therapeutics Business Overview Table 70. Sarepta Therapeutics Product Table 71. Sarepta Therapeutics Revenue in Oligonucleotide Therapeutics Business (2015-2020) (Million US$) Table 72. Sarepta Therapeutics Recent Development Table 73. Jazz Pharmaceuticals Company Details Table 74. Jazz Pharmaceuticals Business Overview Table 75. Jazz Pharmaceuticals Product Table 76. Jazz Pharmaceuticals Revenue in Oligonucleotide Therapeutics Business (2015-2020) (Million US$) Table 77. Jazz Pharmaceuticals Recent Development Table 78. Bausch & Lomb Company Details Table 79. Bausch & Lomb Business Overview Table 80. Bausch & Lomb Product Table 81. Bausch & Lomb Revenue in Oligonucleotide Therapeutics Business (2015-2020) (Million US$) Table 82. Bausch & Lomb Recent Development Table 83. Alnylam Pharmaceuticals Company Details Table 84. Alnylam Pharmaceuticals Business Overview Table 85. Alnylam Pharmaceuticals Product Table 86. Alnylam Pharmaceuticals Revenue in Oligonucleotide Therapeutics Business (2015-2020) (Million US$) Table 87. Alnylam Pharmaceuticals Recent Development Table 88. Dynavax Technologies Company Details Table 89. Dynavax Technologies Business Overview Table 90. Dynavax Technologies Product Table 91. Dynavax Technologies Revenue in Oligonucleotide Therapeutics Business (2015-2020) (Million US$) Table 92. Dynavax Technologies Recent Development Table 93. Kastle therapeutics Company Details Table 94. Kastle therapeutics Business Overview Table 95. Kastle therapeutics Product Table 96. Kastle therapeutics Revenue in Oligonucleotide Therapeutics Business (2015-2020) (Million US$) Table 97. Kastle therapeutics Recent Development Table 98. Akcea Therapeutics Business Overview Table 99. Akcea Therapeutics Product Table 100. Akcea Therapeutics Company Details Table 101. Akcea Therapeutics Revenue in Oligonucleotide Therapeutics Business (2015-2020) (Million US$) Table 102. Akcea Therapeutics Recent Development Table 103. Research Programs/Design for This Report Table 104. Key Data Information from Secondary Sources Table 105. Key Data Information from Primary Sources List of Figures Figure 1. Global Oligonucleotide Therapeutics Market Share by Type: 2020 VS 2026 Figure 2. Antisense Oligonucleotide Features Figure 3. Aptamer Features Figure 4. Other Features Figure 5. Global Oligonucleotide Therapeutics Market Share by Application: 2020 VS 2026 Figure 6. Neuromuscular Diseases Case Studies Figure 7. ATTR Case Studies Figure 8. Hepatic VOD Case Studies Figure 9. Other Case Studies Figure 10. Oligonucleotide Therapeutics Report Years Considered Figure 11. Global Oligonucleotide Therapeutics Market Size YoY Growth 2015-2026 (US$ Million) Figure 12. Global Oligonucleotide Therapeutics Market Share by Regions: 2020 VS 2026 Figure 13. Global Oligonucleotide Therapeutics Market Share by Regions (2021-2026) Figure 14. Porter's Five Forces Analysis Figure 15. Global Oligonucleotide Therapeutics Market Share by Players in 2019 Figure 16. Global Top Oligonucleotide Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Oligonucleotide Therapeutics as of 2019 Figure 17. The Top 10 and 5 Players Market Share by Oligonucleotide Therapeutics Revenue in 2019 Figure 18. North America Oligonucleotide Therapeutics Market Size YoY Growth (2015-2020) (Million US$) Figure 19. Europe Oligonucleotide Therapeutics Market Size YoY Growth (2015-2020) (Million US$) Figure 20. South America Oligonucleotide Therapeutics Market Size YoY Growth (2015-2020) (Million US$) Figure 21. China Oligonucleotide Therapeutics Market Size YoY Growth (2015-2020) (Million US$) Figure 22. Japan Oligonucleotide Therapeutics Market Size YoY Growth (2015-2020) (Million US$) Figure 23. Biogen Total Revenue (US$ Million): 2019 Compared with 2018 Figure 24. Biogen Revenue Growth Rate in Oligonucleotide Therapeutics Business (2015-2020) Figure 25. Sarepta Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018 Figure 26. Sarepta Therapeutics Revenue Growth Rate in Oligonucleotide Therapeutics Business (2015-2020) Figure 27. Jazz Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018 Figure 28. Jazz Pharmaceuticals Revenue Growth Rate in Oligonucleotide Therapeutics Business (2015-2020) Figure 29. Bausch & Lomb Total Revenue (US$ Million): 2019 Compared with 2018 Figure 30. Bausch & Lomb Revenue Growth Rate in Oligonucleotide Therapeutics Business (2015-2020) Figure 31. Alnylam Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018 Figure 32. Alnylam Pharmaceuticals Revenue Growth Rate in Oligonucleotide Therapeutics Business (2015-2020) Figure 33. Dynavax Technologies Total Revenue (US$ Million): 2019 Compared with 2018 Figure 34. Dynavax Technologies Revenue Growth Rate in Oligonucleotide Therapeutics Business (2015-2020) Figure 35. Kastle therapeutics Total Revenue (US$ Million): 2019 Compared with 2018 Figure 36. Kastle therapeutics Revenue Growth Rate in Oligonucleotide Therapeutics Business (2015-2020) Figure 37. Akcea Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018 Figure 38. Akcea Therapeutics Revenue Growth Rate in Oligonucleotide Therapeutics Business (2015-2020) Figure 39. Bottom-up and Top-down Approaches for This Report Figure 40. Data Triangulation Figure 41. Key Executives Interviewed

Biogen Sarepta Therapeutics Jazz Pharmaceuticals Bausch & Lomb Alnylam Pharmaceuticals Dynavax Technologies Kastle therapeutics Akcea Therapeutics